Research and Markets - Cell-Free DNA Market Size and Share Analysis to 2021 with Profiles of Agilent Technologies, Bio-Rad, F. Hoffmann-La Roche, Fluidigm, Illumina, Qiagen, RainDance Technologies & Thermo Fisher Scientific

DUBLIN, May 22, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cell-Free DNA (cfDNA): Market Size and Share Analysis" report to their offering.

The use of cell-free DNA (cfDNA) and liquid biopsies of other analytes has received a huge amount of attention in recent years, due to its potential to revolutionize the diagnosis and treatment of several conditions. The main areas where cfDNA analysis has turned into a major application include non-invasive prenatal testing (NIPT); oncology, circulating tumor DNA (ctDNA); and transplantation, donor-derived cell-free DNA (ddcfDNA).

Cell-Free DNA (cfDNA) Markets focuses on the market for cfDNA analysis instruments, consumables, kits, and related software, which includes the sample preparation products and equipment as well as the next generation sequencing (NGS) and digital polymerase chain reaction (dPCR) systems used for detection.

The report provides complete market information, including current market estimates and forecasts to 2021, as well as:

- Growth Rate for cfDNA Market, 2016-2021
- cfDNA Clinical Diagnostics Market, 2016-2021
- cfDNA Clinical Diagnostics Market Growth Rate, 2016-2021
- cfDNA Market by Region, 2015 (N. America, Europe, Asia-Pacific & ROW)
- cfDNA Instruments and Consumables Revenues by Product Type, 2016 (Consumables, Systems/hardware, Services)
- Market Share by Company of the cfDNA Analysis Instruments, Consumables, and Software Market, 2016

The report provides information on cfDNA analysis products, commenting not only on reagents, consumables, kits, systems, software, and services, but also on oncology cfDNA products, cfDNA transplantation diagnostics, and other products employing cfDNA.

In the cfDNA market there are many technical challenges to overcome, along with a range of competitive, regulatory, and IP issues. Cancer is a dynamic and defiant disease. While NIPT is a proven application, oncology will require much more difficult work and is more uncertain. The variety of potential issues and threats in the market are covered in the challenges and strategic recommendations chapter of the report. The competitive situation, deals, and litigation are covered in respective chapters as well.